Experimental evidence for mTOR being a driving force for malignant progression in ΔS6 and ΔS6:ΔPTEN livers comes from studies showing that chronic activation of mTOR is sufficient to promote HCC in mice [105,106] and accelerates liver tumorigenesis in conjunction with hyperactivated PI3K/Akt [107]. Here, MTOR is linked to hepatocellular carcinoma.